314 results
8-K
EX-99.1
ORKA
Oruka Therapeutics Inc.
14 Nov 24
Report of Independent Registered Public Accounting Firm
4:56pm
initiation fee of $0.8 million was due to Paragon. This amount was recognized as a research and development expense during the period ended March 31 … to ORKA-002 incurred by Paragon between January 1, 2024 and March 6, 2024. This amount was recognized as a research and development expenses during
8-K
EX-99.1
ORKA
Oruka Therapeutics Inc.
13 Sep 24
Oruka Therapeutics Announces $200 Million Private Placement
4:02pm
financing for research and development, general corporate expenses, and working capital needs. The Company expects that its cash will fund its operating plan
8-K
EX-99.3
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
Research and development(1) General and administrative(2) Total operating expenses Loss from operations Other expense Interest expense(3) Total other … research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require
8-K
EX-10.25
fi12szo0p7d
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-99.5
3x7svs hkq
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-99.4
792drhv
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
mf63xotuj
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-99.2
rs6uj2dc2fvpfrn3n8o3
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
425
hda7hgs2fs yg82r7o
26 Aug 24
Business combination disclosure
7:53pm
425
EX-99.1
4372 1pzb
26 Aug 24
Business combination disclosure
7:53pm
8-K
v282dp1
26 Aug 24
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
7:51pm
8-K
EX-99.1
cmb9dxy9np9p
26 Aug 24
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
7:51pm
8-K
kfn9pbciuq8esb37q7ig
23 Aug 24
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
4:35pm
8-K
EX-99.1
75f5v7o p2e703krgw7
23 Aug 24
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
4:35pm
425
i3rcd9w
16 Aug 24
Business combination disclosure
4:27pm
425
EX-99.1
msd plk9zau0xg
16 Aug 24
Business combination disclosure
4:27pm
8-K
EX-99.1
n1eb7y5vvreij
16 Aug 24
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
4:25pm
8-K
hgnjdp6e0 xqtt
16 Aug 24
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
4:25pm